Aligos Therapeutics, Inc. Investing Cash Flow
Aligos Therapeutics, Inc. (ALGS) reported Investing Cash Flow of $59.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $25.00M.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $34.93M.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$2.02M, a 110.12% decline year-over-year.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $47.68M, a 358.58% increase year-over-year.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$37.83M.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$18.28M, a 140.64% decline from fiscal 2023.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $44.98M.
- Aligos Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$26.29M, a 970.05% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $59.93M 10-Q · filed 2026-08-06 | $57.91M derived: sum of 3 quarters · filed 2026-08-06 | $105.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $34.93M 10-Q · filed 2026-05-07 | $32.91M derived: sum of 2 quarters · filed 2026-05-07 | $80.59M derived: sum of 3 quarters · filed 2026-05-07 | $41.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $45.66M derived: sum of 2 quarters · filed 2026-03-05 | $6.24M derived: sum of 3 quarters · filed 2026-08-06 | -$37.83M 10-K · filed 2026-03-05 |
| 2025-09-30 | $47.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.26M derived: sum of 2 quarters · filed 2026-08-06 | -$35.80M 10-Q · filed 2025-11-06 | -$15.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$39.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$83.49M 10-Q · filed 2026-08-06 | -$63.52M derived: sum of 3 quarters · filed 2026-08-06 | -$53.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$44.07M 10-Q · filed 2026-05-07 | -$24.09M derived: sum of 2 quarters · filed 2026-05-07 | -$13.70M derived: sum of 3 quarters · filed 2026-05-07 | $26.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $19.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $30.37M derived: sum of 2 quarters · filed 2026-03-05 | $70.36M derived: sum of 3 quarters · filed 2026-03-05 | -$18.28M 10-K · filed 2026-03-05 |
| 2024-09-30 | $10.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $50.39M derived: sum of 2 quarters · filed 2025-11-06 | -$38.25M 10-Q · filed 2025-11-06 | -$38.26M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $39.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$48.65M 10-Q · filed 2025-08-06 | -$48.66M derived: sum of 3 quarters · filed 2025-08-06 | -$48.66M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$88.64M 10-Q · filed 2025-05-06 | -$88.65M derived: sum of 2 quarters · filed 2025-05-06 | -$88.66M derived: sum of 3 quarters · filed 2025-05-06 | -$63.65M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$16.00K derived: sum of 2 quarters · filed 2025-03-10 | $24.99M derived: sum of 3 quarters · filed 2025-03-10 | $44.98M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $25.00M derived: sum of 2 quarters · filed 2024-11-06 | $44.99M 10-Q · filed 2024-11-06 | $56.59M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $45.00M 10-Q · filed 2024-08-06 | $56.60M derived: sum of 3 quarters · filed 2024-08-06 | $89.08M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $19.99M 10-Q · filed 2024-05-07 | $31.60M derived: sum of 2 quarters · filed 2024-05-07 | $64.08M derived: sum of 3 quarters · filed 2024-05-07 | $54.10M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $44.09M derived: sum of 2 quarters · filed 2024-03-12 | $34.11M derived: sum of 3 quarters · filed 2024-03-12 | -$26.29M 10-K · filed 2024-03-12 |
| 2022-09-30 | $32.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $22.51M derived: sum of 2 quarters · filed 2023-11-02 | -$37.90M 10-Q · filed 2023-11-02 | -$54.38M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$9.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$70.38M 10-Q · filed 2023-08-03 | -$86.86M derived: sum of 3 quarters · filed 2023-08-03 | -$86.90M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$60.40M 10-Q · filed 2023-05-04 | -$76.88M derived: sum of 2 quarters · filed 2023-05-04 | -$76.92M derived: sum of 3 quarters · filed 2023-05-04 | -$67.08M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$16.52M derived: sum of 2 quarters · filed 2023-03-09 | -$6.67M derived: sum of 3 quarters · filed 2023-03-09 | $3.02M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $9.81M derived: sum of 2 quarters · filed 2022-11-02 | $19.50M 10-Q · filed 2022-11-02 | $34.44M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $9.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $19.54M 10-Q · filed 2022-08-04 | $34.48M derived: sum of 3 quarters · filed 2022-08-04 | $61.13M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $9.69M 10-Q · filed 2022-05-04 | $24.63M derived: sum of 2 quarters · filed 2022-05-04 | $51.29M derived: sum of 3 quarters · filed 2022-05-04 | $66.22M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $14.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $41.59M derived: sum of 2 quarters · filed 2022-03-10 | $56.52M derived: sum of 3 quarters · filed 2022-03-10 | $32.76M 10-K · filed 2022-03-10 |
| 2020-09-30 | $26.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $41.59M derived: sum of 2 quarters · filed 2021-11-04 | $17.82M 10-Q · filed 2021-11-04 | -$3.99M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $14.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$8.84M 10-Q · filed 2021-08-05 | -$30.65M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$23.77M 10-Q · filed 2021-05-10 | -$45.58M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | -$21.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $6.79M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $28.60M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |